Trial Profile
Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 28 Oct 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.